Premium
Induced CD25 Expression in a Human B‐Lymphoma Cell Line Transfected with the Epstein‐Barr Virus Nuclear Antigen 2 Gene
Author(s) -
Harada Shizuko,
Yanagi Kazuo
Publication year - 1992
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1992.tb02046.x
Subject(s) - transfection , biology , cell culture , antigen , microbiology and biotechnology , cd23 , epstein–barr virus , il 2 receptor , virus , cell , gene expression , t cell , virology , gene , antibody , immunology , immune system , genetics , immunoglobulin e
Two EBV‐negative human B‐lymphoma cell lines, BJAB and DG75, were transfected with an Epstein‐Barr virus (EBV) nuclear antigen 2 (EBNA‐2) gene, which plays a critical role in the EBV‐induced immortalization of primary B lymphocytes. Furthermore, DG75 cells were co‐transfected with the EBNA‐2 gene and a latent membrane protein (LMP) gene. Expression of eight surface antigens on the resultant EBNA‐2‐expressing cell clones was analyzed by flowcytometry. None of the EBNA‐2‐expressing cell clones derived from BJAB and DG75 showed a significant increase in the expression of cell surface marker CD23, of which enhancement by EBNA‐2 in a different EBV‐negative human B cell line, Louckes, was previously reported. Expression of CD25 (IL‐2R/Tac) on cell surface, however, was induced in two of six DG75‐derived cell clones. One of the two CD25‐induced cell clones was expressing EBNA‐2 only, and the other was co‐expressing EBNA‐2 and LMP. The results suggest that EBNA‐2 has a potential to up‐regulate CD25 independently of CD23 on human B cells.